Analysis of Secondary Leukemia and Myelodysplastic Syndrome After Chemotherapy for Solid Organ Tumors Using the Food and Drug Administration Adverse Event Reporting System (FAERS)

CONCLUSIONS: Our study clarified the risks of leukemia and myelodysplastic syndrome for several anticancer drugs in patients with solid tumors. Our data may aid in the assessment of the risks of secondary leukemia and myelodysplastic syndrome when medical oncologists, clinical pharmacists, and patients select chemotherapy regimens.PMID:34644524 | DOI:10.18433/jpps31862
Source: J Pharm Pharm Sci - Category: Drugs & Pharmacology Authors: Source Type: research

Related Links:

More News: Cancer | Cancer & Oncology | Cervical Cancer | Chemotherapy | Colon Cancer | Colorectal Cancer | Drugs & Pharmacology | Endometrial Cancer | Esophagus Cancer | Gastric (Stomach) Cancer | Gastroenterology | Hematology | Leukemia | Myelodysplastic Syndrome | Non-Small Cell Lung Cancer | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Study | USA Health